HLS TherapeuticsTSX:HLS -2.26%62 PB Ratio is 1.68 as of Jun. 24, 2026, which is at its 10-year median of 1.68. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.46 (Fairly Valued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, HLS Therapeutics ranks better than 54.23% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), HLS Therapeutics's share price is C$4.32. HLS Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was C$2.57. Hence, HLS Therapeutics's PB Ratio of today is 1.68.
Good Sign:
HLS Therapeutics Inc stock PB Ratio (=1.69) is close to 1-year low of 1.59.
The historical rank and industry rank for HLS Therapeutics's PB Ratio or its related term are showing as below:
TSX:HLS'
s PB Ratio Range Over the Past 10 Years
Min: 0.29 Med: 1.68 Max: 3.21
Current: 1.68
During the past 13 years, HLS Therapeutics's highest PB Ratio was 3.21. The lowest was 0.29. And the median was 1.68.
TSX:HLS's PB Ratio is ranked better than 54.23% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs TSX:HLS: 1.68
During the past 12 months, HLS Therapeutics's average Book Value Per Share Growth Rate was -15.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -19.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -17.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of HLS Therapeutics was 44.50% per year. The lowest was -20.40% per year. And the median was 3.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
HLS Therapeutics PB Ratio Related Terms
HLS Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
HLS Therapeutics (TSX:HLS) has a PB Ratio of 1.68 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HLS Therapeutics and its competitors. This is near median its historical median of 1.68. Over the past decade, HLS Therapeutics' PB Ratio has ranged from 0.29 to 3.21. According to the industry distribution chart, HLS Therapeutics ranks #422 out of 922 companies in the Drug Manufacturers industry, placing it in the top 45.8%.
Is HLS Therapeutics' PB Ratio too high?
HLS Therapeutics' current PB Ratio of 1.68 is near median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 3.21. The Drug Manufacturers industry median PB Ratio is 1.88. HLS Therapeutics' value of 1.68 is 10.6% below this industry median. Based on the distribution chart, HLS Therapeutics ranks #422 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #422 out of 922 companies for PB Ratio. This puts HLS Therapeutics in the upper half of its industry. The industry median PB Ratio is 1.88. HLS Therapeutics' value of 1.68 is 10.6% below this benchmark. Historically, HLS Therapeutics' own PB Ratio has ranged from 0.29 to 3.21 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 1.88, HLS Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current PB Ratio of 1.68 is 10.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current PB Ratio is 1.68, which is near median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.46, compared to a current price of C$4.32 — trading 3.1% below its estimated fair value. The current PB Ratio is 1.68, which is near median its 10-year median of 1.68 and 10.6% below the Drug Manufacturers industry median of 1.88. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current PB Ratio is 1.68 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.32 is trading 3.1% below its estimated GF Value™ of C$4.46.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
PB Ratio: 1.68 (near median its 10-year median of 1.68)
GF Value™: C$4.46 vs. price of C$4.32 (3.1% below fair value)
Industry Position: 10.6% below the Drug Manufacturers median (#422 of 922)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score
Get the complete analysis for TSX:HLS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
